James Donohue, Senior Digital Health Lead, Genentech
Jenny Fisher, Sr. Principal, Digital Business Lead, Oncology, Genentech

Executive leaders discuss where AI, digital biomarkers, decentralized trials, tokenization, digital twins, and software-enabled research have delivered measurable value - and where expectations have outpaced reality.

Peter St. Wecker, Clinical Development Lead, Neurology, UCB
Mukul Virmani, Director , Clinical Data Science - AI Research Center, Gilead Sciences
Paulius Ojeras, VP, Clinical Operations, Perceive Biotherapeutics
Speaker TBA, QuantHealth

Practical lessons from implementing AI across clinical development organizations. What scaled? What failed? What surprised us?

Speaker TBA

As clinical trials grow in complexity and geographic scope, successful execution increasingly hinges on engagement—of patients, investigators, and study teams. Artificial Intelligence (AI) offers transformative opportunities to streamline communication, personalize support, and optimize operations across the trial lifecycle. This session explores real-world and emerging AI use cases for improving engagement in clinical trials:

• For Patients: AI-driven personalization and behavioral insights can boost enrollment, retention, and adherence.
• For Investigators: Intelligent tools can reduce administrative burden and enhance decision-making at the site level.
• For Study Teams: Generative and agentic AI can coordinate trial logistics, detect risks early, and ensure protocol compliance.

Drawing from innovations in conversational AI, this talk offers a pragmatic view of how AI is not just automating clinical trials, but making them more human-centric.
Shun Zhang, Director of AI, AstraZeneca

• Risk-based monitoring exists because we couldn't review everything. Agents can.
• Oversight moves from periodic review to continuous reasoning — agents investigate signals, not just flag thresholds.
• Trust comes from auditability, not autonomy. Humans still own the judgment calls.

Dr. Michelle Longmire, MD, Co-Founder and CEO, Medable

This panel discussion will explore which innovations have crossed from pilot to operational practice. Examine adoption, ROI, patient benefit, and organizational readiness.

Moderated by: Tom Switzer, Head, Digital Health, Genentech

Real trial participants and caregivers share raw, personal experiences — what helped, what harmed, and what still feels performative. Discuss how patient advisory boards, return of results, financial burdens, and cultural respect can make or break trust.

This panel will bring together 3 patients and 1 caregiver to discuss their lived clinical trial experiences.

Moderated by Rozanno Gonzales, Clinical Innovation and Technology, Genentech

One patient’s end-to-end research journey, highlighting moments where technology created value, and where it created friction.

This presentation will explore how sites are adapting workflows, staffing, and technology to support modern clinical research.

Laura O'Donnell, Sr. Director, Head, Global Site Engagement, GSK

• What are the biggest barriers sites faces in starting trials faster, and where could sponsors make the greatest difference?
• What do you wish pharma sponsors understood better about the day-to-day realities of running clinical trials at a site?
• Which technologies have actually improved patient recruitment, retention, or trial execution—and which have created more burden than value?
• If you could change one thing about the sponsor–site relationship to make trials more efficient and patient-centric, what would you change?

Lauren Dickey, Clinical Research Supervisor, UCSF
Colin Sauder, Chief Scientific Officer, Adams Clinical

Sponsors, technology partners, and patient representatives discuss practical strategies for reducing burden while improving engagement.

Panelists TBA

Executive vision for the next generation of clinical research and why responsible innovation requires patient trust, collaboration, and measurable outcomes.

Luca Finelli, VP, Global Head of Digital Endpoints and Patient Centered Solutions, Roche

This panel will explore how connected devices can transform safety monitoring from periodic snapshots into continuous insight—helping sponsors improve patient safety, strengthen data quality, and de-risk clinical development. This panel will address what it takes to move from promise to practical, scalable implementation.

Sebastian Jayaraj, Sr Director, Digital Health, BMS

Moderated by: John Rootenberg, Principal Director, Digital Safety & Decision Support, Genentech

Connecting patient journeys across studies while preserving privacy. Discussion of tokenization, federated learning, and trusted data ecosystems.

Moderated by Kim Barnholt, Executive Director, Data and Clinical Innovation, Genentech

This presentation will look into the current subspace of PRO among other phenomics data sources and discuss opportunities and challenges in the era of AI.

Saeid Shahraz, Director, HEOR, Clinical Outcome Assessment Strategy & Analytics, Gilead Sciences

Thomas Bengtsson, Executive Director, Product Development (Oncology, Digital Endpoints), Genentech

This discussion will explore combining digital biomarkers, EHRs, PROs, imaging, genomics, and real-world data into continuous evidence generation.

Thomas Bengtsson, Executive Director, Product Development (Oncology, Digital Endpoints), Genentech
Saeid Shahraz, Director, HEOR, Clinical Outcome Assessment Strategy & Analytics, Gilead Sciences

Practical lessons from two years of implementing and using agentic AI in a lean clinical trial execution. What worked, what didn't, and how understanding how AI actually works changed our approach where and how we deploy it.

Paulius Ojeras, VP, Clinical Operations, Perceive Biotherapeutics

FDA, legal, and industry perspectives on AI governance, digital endpoints, tokenized data, digital biomarkers, and decentralized oversight.

Speakers TBA

This panel discussion will share innovations in reaching rural, indigenous, low-literacy, and under-resourced communities for research participation, with concrete tools and partnerships.

Meg McKenzie, Director, Population Sciences, Genentech
Lloryn Hubbard, Director, Clinical Trial Diversity, Daiichi Sankyo

Moderated by: Archie Yellow-Duke, Sr. Medical Director, US Medical Population Science & Health, Genentech

Interactive closing discussion where patients, investigators, sponsors, regulators, and technology leaders design the ideal clinical trial of the future using the day’s insights

James Donohue, Senior Digital Health Lead, Genentech
Jenny Fisher, Sr. Principal, Digital Business Lead, Oncology, Genentech

James Donohue, Senior Digital Health Lead, Genentech
Jenny Fisher, Sr. Principal, Digital Business Lead, Oncology, Genentech